Bridgefront Capital’s Cellebrite CLBT Stock Holding History

Bridgefront Capital’s Portfolio CLBT Stock Details CLBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-10,901	Closed	-$184K	–	613
2024 Q3	$184K	Buy	+10,901	New	+$162K	0.07%	465

Other funds holding CLBT

TWCM

True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Axon Enterprise Scottsdale, Arizona $19.1M AUM 8.75% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

Crosslink Capital Menlo Park, California $1.35B AUM 35.86% 1-Year Est. Return

Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return

Bridgefront Capital's CLBT Position: Q4 2024 in Review

Bridgefront Capital sold out of Cellebrite (CLBT) in Q4 2024, closing a stake of 10,901 shares — an estimated $184K sold.

Bridgefront Capital first reported a position in CLBT in Q3 2024 and held it in 1 quarter. The position peaked at $184K in Q3 2024. 191 funds tracked by Wall St. Rank hold CLBT as of Q4 2024.

Bridgefront Capital reported no remaining Cellebrite position as of Q4 2024 after selling out during the quarter.
Bridgefront Capital sold 10,901 Cellebrite shares in Q4 2024, an estimated $184K.
Bridgefront Capital first reported a position in Cellebrite in Q3 2024 and held it in 1 quarter.
Bridgefront Capital's Cellebrite position peaked at $184K in Q3 2024.
191 funds tracked by Wall St. Rank held Cellebrite as of Q4 2024.

Based on Bridgefront Capital's 13F filing for Q4 2024, filed 14 Feb 2025.